Education
About Us
Working with TipRanks
Follow Us
Baudax Bio (BXRXQ)
OTHER OTC:BXRXQ
BXRXQ Stock Chart & Stats
$0.01
$0.00(0.00%)
At close: 4:00 PM EST
$0.01
$0.00(0.00%)
Day’s Range― - ―
52-Week Range<$0.01 - $1.43
Previous CloseN/A
Volume10.20K
Average Volume (3M)N/A
Market Cap
$44.00
Enterprise ValueN/A
Total Cash (Recent Filing)$363.00K
Total Debt (Recent Filing)$8.10M
Price to Earnings (P/E)―
Beta-173.75
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-9.16
Shares Outstanding43,593,082
10 Day Avg. VolumeN/A
30 Day Avg. VolumeN/A
Financial Highlights & Ratios
PEG Ratio0.00
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
BXRXQ FAQ
What was Baudax Bio’s price range in the past 12 months?
Baudax Bio lowest stock price was <$0.01 and its highest was $1.43 in the past 12 months.
What is Baudax Bio’s market cap?
Baudax Bio’s market cap is $44.00.
When is Baudax Bio’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Baudax Bio’s earnings last quarter?
Currently, no data Available
Is Baudax Bio overvalued?
According to Wall Street analysts Baudax Bio’s price is currently Overvalued.
Does Baudax Bio pay dividends?
Baudax Bio does not currently pay dividends.
What is Baudax Bio’s EPS estimate?
Baudax Bio’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Baudax Bio have?
Baudax Bio has 43,593,082 shares outstanding.
What happened to Baudax Bio’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Baudax Bio?
Currently, no hedge funds are holding shares in BXRXQ
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Baudax Bio
Baudax Bio, Inc., a pharmaceutical company, develops and commercializes products for hospital and other acute care related settings. The company offers ANJESO (meloxicam) injection for the management of moderate to severe pain, alone or in combination with other non-NSAID analgesics. It also develops BX1000, an intermediate-acting neuromuscular blocking agent (NMB) that is in phase II clinical trial; BX2000, an ultra- short acting NMB, which is in phase I clinical trial, as well as a proprietary blockade reversal agent; and BX3000, a NMB reversal agent that is in preclinical studies. Baudax Bio, Inc. was incorporated in 2019 and is based in Malvern, Pennsylvania. On February 22, 2024, Baudax Bio, Inc. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the Eastern District of Pennsylvania.
Biodexa Pharmaceuticals
―
Nuwellis
―
Salarius Pharmaceuticals
―
Scinai Immunotherapeutics
―
Oragenics
―
Ownership Overview
―
Insiders
―
Mutual Funds
<0.01% Other Institutional Investors
100.00% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---